FOLH1 and neoplasm: Anti-PSMA Humabody conjugates were not able to demonstrate comparable remissions in a tumor model of high expressing cells (⁓106 receptors/cell), which is similar to the HER2 expression levels of the NCI-N87 cells in this study.